These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 39131660)

  • 1. Five-Year Independent Patient-Level Mortality Analysis of the Pooled ILLUMENATE Pivotal and EU Randomized Controlled Trials.
    Lyden SP; Brodmann M; Schroeder H; Holden A; Ouriel K; Tarra TR; Gray WA
    J Soc Cardiovasc Angiogr Interv; 2023; 2(4):100634. PubMed ID: 39131660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Four-year patient-level pooled mortality analysis of the ILLUMENATE US Pivotal and EU randomized controlled trials.
    Lyden SP; Brodmann M; Parikh SA; Krishnan P; Schroeder H; Werner M; Holden A; Ouriel K; Tarra T; Gray WA
    J Vasc Surg; 2022 Feb; 75(2):600-607. PubMed ID: 34506898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mortality Assessment of Paclitaxel-Coated Balloons: Patient-Level Meta-Analysis of the ILLUMENATE Clinical Program at 3 Years.
    Gray WA; Jaff MR; Parikh SA; Ansel GM; Brodmann M; Krishnan P; Razavi MK; Vermassen F; Zeller T; White R; Ouriel K; Adelman MA; Lyden SP
    Circulation; 2019 Oct; 140(14):1145-1155. PubMed ID: 31567024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stellarex Drug-Coated Balloon for the Treatment of Peripheral Artery Disease: Five-Year Results from the ILLUMENATE Pivotal Randomized Controlled Trial.
    Krishnan P; Faries P; Niazi K; Sachar R; Jain A; Brodmann M; Werner M; Holden A; Tarricone A; Tarra T; Lyden S
    Am J Cardiol; 2024 Sep; 227():83-90. PubMed ID: 39019203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No Mortality Signal With Stellarex Low-Dose Paclitaxel DCB: ILLUMENATE Pivotal 4-Year Outcomes.
    Lyden SP; Faries PL; Niazi KAK; Sachar R; Jain A; Brodmann M; Werner M; Sood A; Krishnan P
    J Endovasc Ther; 2022 Dec; 29(6):929-936. PubMed ID: 35000470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stellarex Drug-Coated Balloon for Treatment of Femoropopliteal Disease: Twelve-Month Outcomes From the Randomized ILLUMENATE Pivotal and Pharmacokinetic Studies.
    Krishnan P; Faries P; Niazi K; Jain A; Sachar R; Bachinsky WB; Cardenas J; Werner M; Brodmann M; Mustapha JA; Mena-Hurtado C; Jaff MR; Holden AH; Lyden SP
    Circulation; 2017 Sep; 136(12):1102-1113. PubMed ID: 28729250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-Dose Paclitaxel-Coated Versus Uncoated Percutaneous Transluminal Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease: One-Year Results of the ILLUMENATE European Randomized Clinical Trial (Randomized Trial of a Novel Paclitaxel-Coated Percutaneous Angioplasty Balloon).
    Schroeder H; Werner M; Meyer DR; Reimer P; Krüger K; Jaff MR; Brodmann M;
    Circulation; 2017 Jun; 135(23):2227-2236. PubMed ID: 28424223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mortality Not Correlated With Paclitaxel Exposure: An Independent Patient-Level Meta-Analysis of a Drug-Coated Balloon.
    Schneider PA; Laird JR; Doros G; Gao Q; Ansel G; Brodmann M; Micari A; Shishehbor MH; Tepe G; Zeller T
    J Am Coll Cardiol; 2019 May; 73(20):2550-2563. PubMed ID: 30690141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The IN.PACT DEEP Clinical Drug-Coated Balloon Trial: 5-Year Outcomes.
    Zeller T; Micari A; Scheinert D; Baumgartner I; Bosiers M; Vermassen FEG; Banyai M; Shishehbor MH; Wang H; Brodmann M;
    JACC Cardiovasc Interv; 2020 Feb; 13(4):431-443. PubMed ID: 32081236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of Paclitaxel-Coated Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease.
    Ouriel K; Adelman MA; Rosenfield K; Scheinert D; Brodmann M; Peña C; Geraghty P; Lee A; White R; Clair DG
    JACC Cardiovasc Interv; 2019 Dec; 12(24):2515-2524. PubMed ID: 31575518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel exposure: Long-term safety and effectiveness of a drug-coated balloon for claudication in pooled randomized trials.
    Schneider PA; Brodmann M; Mauri L; Laird J; Soga Y; Micari A; Ansel G; Shishehbor MH; Krishnan P; Gao Q; Ouriel K; Zeller T
    Catheter Cardiovasc Interv; 2020 Nov; 96(5):1087-1099. PubMed ID: 32830913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Clinical Effectiveness of a Drug-Coated Balloon for the Treatment of Femoropopliteal Lesions.
    Laird JA; Schneider PA; Jaff MR; Brodmann M; Zeller T; Metzger DC; Krishnan P; Scheinert D; Micari A; Wang H; Masters M; Tepe G
    Circ Cardiovasc Interv; 2019 Jun; 12(6):e007702. PubMed ID: 31195825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three-Year Results of the IN.PACT SFA Japan Trial Comparing Drug-Coated Balloons With Percutaneous Transluminal Angioplasty.
    Soga Y; Iida O; Urasawa K; Saito S; Jaff MR; Wang H; Ookubo H; Yokoi H
    J Endovasc Ther; 2020 Dec; 27(6):946-955. PubMed ID: 32865145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durability of Treatment Effect Using a Drug-Coated Balloon for Femoropopliteal Lesions: 24-Month Results of IN.PACT SFA.
    Laird JR; Schneider PA; Tepe G; Brodmann M; Zeller T; Metzger C; Krishnan P; Scheinert D; Micari A; Cohen DJ; Wang H; Hasenbank MS; Jaff MR;
    J Am Coll Cardiol; 2015 Dec; 66(21):2329-2338. PubMed ID: 26476467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stellarex drug-coated balloon for treatment of femoropopliteal arterial disease-The ILLUMENATE Global Study: 12-Month results from a prospective, multicenter, single-arm study.
    Schroë H; Holden AH; Goueffic Y; Jansen SJ; Peeters P; Keirse K; Ito W; Vermassen F; Micari A; Blessing E; Jaff MR; Zeller T
    Catheter Cardiovasc Interv; 2018 Feb; 91(3):497-504. PubMed ID: 29086462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment Effect of Drug-Coated Balloons Is Durable to 3 Years in the Femoropopliteal Arteries: Long-Term Results of the IN.PACT SFA Randomized Trial.
    Schneider PA; Laird JR; Tepe G; Brodmann M; Zeller T; Scheinert D; Metzger C; Micari A; Sachar R; Jaff MR; Wang H; Hasenbank MS; Krishnan P;
    Circ Cardiovasc Interv; 2018 Jan; 11(1):e005891. PubMed ID: 29326153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Patient-Level, Pooled Analysis of Mortality Rates With the Passeo-18 Lux Paclitaxel Drug-Coated Balloon in Peripheral Arterial Disease.
    Forrestal BJ; Zhang C; Case BC; Yerasi C; Craig PE; Torguson R; Bernardo NL; Waksman R
    Cardiovasc Revasc Med; 2021 Dec; 33():49-54. PubMed ID: 34090794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Total IN.PACT drug-coated balloon initiative reporting pooled imaging and propensity-matched cohorts.
    Shishehbor MH; Schneider PA; Zeller T; Razavi MK; Laird JR; Wang H; Tieché C; Parikh SA; Iida O; Jaff MR
    J Vasc Surg; 2019 Oct; 70(4):1177-1191.e9. PubMed ID: 31543165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Five-Year Outcomes of Post-Drug-Coated Balloon Angioplasty Dissection in Complex Femoropopliteal Artery Disease.
    Ren H; Liu J; Zhang J; Zhuang B; Fu W; Wu D; Wang F; Zhao Y; Guo P; Bi W; Wang S; Guo W
    Int J Gen Med; 2021; 14():4197-4207. PubMed ID: 34385840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. German Center Subanalysis of the LEVANT 2 Global Randomized Study of the Lutonix Drug-Coated Balloon in the Treatment of Femoropopliteal Occlusive Disease.
    Scheinert D; Schmidt A; Zeller T; Müller-Hülsbeck S; Sixt S; Schröder H; Weiss N; Ketelsen D; Ricke J; Steiner S; Rosenfield K
    J Endovasc Ther; 2016 Jun; 23(3):409-16. PubMed ID: 27117972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.